⌘K
Loading ticker…
Cyclerion Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Cyclerion Therapeutics, Inc. Common Stock (CYCN) has a 3-month relative strength percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 73. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 0.93×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 97, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
CYCN appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $25K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $25K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYCN Jan avg: 5.15% median: 4.65% win: 75% σ: 13.30% n: 4 2022-04-12 → 2026-05-29 | CYCN Feb avg: -8.89% median: -1.84% win: 0% σ: 15.38% n: 4 2022-04-12 → 2026-05-29 | CYCN Mar avg: -4.56% median: 0.15% win: 50% σ: 21.08% n: 4 2022-04-12 → 2026-05-29 | CYCN Apr avg: 15.02% median: -11.56% win: 40% σ: 62.21% n: 5 2022-04-12 → 2026-05-29 | CYCN May avg: -13.14% median: -15.47% win: 0% σ: 7.49% n: 5 2022-04-12 → 2026-05-29 | CYCN Jun avg: -6.86% median: -8.57% win: 25% σ: 7.85% n: 4 2022-04-12 → 2026-05-29 (current) | CYCN Jul avg: 24.81% median: 23.36% win: 50% σ: 47.72% n: 4 2022-04-12 → 2026-05-29 | CYCN Aug avg: -6.28% median: -9.65% win: 25% σ: 13.24% n: 4 2022-04-12 → 2026-05-29 | CYCN Sep avg: -5.21% median: -5.81% win: 25% σ: 5.82% n: 4 2022-04-12 → 2026-05-29 | CYCN Oct avg: -16.78% median: -21.34% win: 25% σ: 20.26% n: 4 2022-04-12 → 2026-05-29 | CYCN Nov avg: 4.30% median: -15.83% win: 25% σ: 45.78% n: 4 2022-04-12 → 2026-05-29 | CYCN Dec avg: 12.37% median: 13.37% win: 50% σ: 43.81% n: 4 2022-04-12 → 2026-05-29 |